refractory acute promyelocytic leukemia successfully treated with combination therapy of arsenic trioxide and tamibarotene: a case report
Clicks: 87
ID: 238151
2016
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
22.8
/100
76 views
6 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
A 40-year-old male developed refractory acute promyelocytic leukemia (APL) after various treatments including all-trans retinoic acid, tamibarotene, arsenic trioxide (As2O3), conventional chemotherapy, and autologous peripheral blood stem cell transplantation. We attempted to use both tamibarotene and As2O3 as a combination therapy, and he achieved molecular complete remission. Grade 2 prolongation of the QTc interval on the electrocardiogram was observed during the therapy. The combination therapy of As2O3 and tamibarotene may be effective and tolerable for treating refractory APL cases who have no treatment options, even when they have previously been treated with tamibarotene and As2O3 as a single agent.
| Reference Key |
kojima2016leukemiarefractory
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Minoru Kojima;Daisuke Ogiya;Akifumi Ichiki;Ryujiro Hara;Jun Amaki;Hidetsugu Kawai;Hiroki Numata;Ai Sato;Mitsuki Miyamoto;Rikio Suzuki;Shinichiro Machida;Hiromichi Matsushita;Yoshiaki Ogawa;Hiroshi Kawada;Kiyoshi Ando |
| Journal | urology annals |
| Year | 2016 |
| DOI |
10.1016/j.lrr.2016.01.001
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.